|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1977-4-28
|
|
pubmed:abstractText |
23 patients with hyperlipidemia and hyperuricemia received acetamidoethyl-(4-chlorophenyl)-(trifluoromethylphenoxy)-acetate (halofenate), a clofibrate derivative, and probenecid or probenecid and placebo over 36 weeks following a placebo period of 6 weeks. Halofenate compared with probenecid lowered elevated serum uric acid levels satisfactorily to a therapeutic level between 5 and 6 mg/100 ml. Serum triglyceride levels were not always lowered sufficiently, serum cholesterol levels were not influenced.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0004-4172
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2221-4
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:798591-Cholesterol,
pubmed-meshheading:798591-Clinical Trials as Topic,
pubmed-meshheading:798591-Female,
pubmed-meshheading:798591-Glycolates,
pubmed-meshheading:798591-Halofenate,
pubmed-meshheading:798591-Humans,
pubmed-meshheading:798591-Hyperlipidemias,
pubmed-meshheading:798591-Male,
pubmed-meshheading:798591-Probenecid,
pubmed-meshheading:798591-Triglycerides,
pubmed-meshheading:798591-Uric Acid
|
|
pubmed:year |
1976
|
|
pubmed:articleTitle |
[Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
English Abstract,
Randomized Controlled Trial,
Controlled Clinical Trial
|
